Paul Tudor Jones's TRVI Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 68,481 shares of Trevi Therapeutics, Inc. (TRVI) worth $857,382, representing 0.00% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Paul Tudor Jones has initiated a new position in TRVI, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Trevi Therapeutics (TRVI) Holding Value Over Time
Track share changes against reported price movement
Quarterly Trevi Therapeutics (TRVI) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +68,481 | New Buy | 68,481 | $12.52 |
Paul Tudor Jones's Trevi Therapeutics Investment FAQs
Paul Tudor Jones first purchased Trevi Therapeutics, Inc. (TRVI) in Q4 2025, acquiring 68,481 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Trevi Therapeutics, Inc. (TRVI) for 1 quarters since Q4 2025.
Paul Tudor Jones's largest addition to Trevi Therapeutics, Inc. (TRVI) was in Q4 2025, adding 68,481 shares worth $857,382.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 68,481 shares of Trevi Therapeutics, Inc. (TRVI), valued at approximately $857,382.
As of the Q4 2025 filing, Trevi Therapeutics, Inc. (TRVI) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Trevi Therapeutics, Inc. (TRVI) was 68,481 shares, as reported at the end of Q4 2025.